Open Access

Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling

  • Authors:
    • Ping Yang
    • Fenghua Shi
    • Yanli Zhang
  • View Affiliations

  • Published online on: December 22, 2022     https://doi.org/10.3892/etm.2022.11773
  • Article Number: 74
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Periodontitis is the chronic inflammation of the periodontal tissue. The present study aimed to investigate the role of baricitinib, a Janus kinase (JAK)1/2 inhibitor, in periodontitis by using a lipopolysaccharide (LPS)‑induced human periodontal ligament stem cell (PDLSC) model. The viability of PDLSCs stimulated by LPS was assessed in the presence of baricitinib by Cell Counting Kit‑8 assay. The induction of oxidative stress was evaluated by detecting the intracellular reactive oxygen species (ROS) levels, superoxide dismutase (SOD) activity and glutathione (GSH) content. ELISA and reverse transcription‑quantitative PCR were used to determine the levels of inflammatory factors TNF‑α, IL‑1β and IL‑6. Alkaline phosphatase (ALP) activity and alizarin red staining were used to assess the osteogenic differentiation of PDLSCs. The expression levels of osteogenic differentiation‑ and JAK/signal transducer and activator of transcription (STAT) signaling‑associated proteins were estimated with western blotting. RO8191, an agonist of the JAK/STAT pathway, was used to treat PDLSCs to investigate the regulatory mechanism of baricitinib. The results indicated that baricitinib elevated the LPS‑induced decrease in cell viability. LPS‑triggered oxidative stress and inflammation were inhibited by baricitinib, as demonstrated by the decreased levels of ROS, TNF‑α, IL‑1β, IL‑6 and increased levels of SOD and GSH. In addition, baricitinib caused a marked elevation in ALP activity and mineralization ability of PDLSCs, as determined by the upregulated osteocalcin and Runt‑related transcription factor 2 expression. Moreover, the expression levels of phosphorylated (p)‑JAK1, p‑JAK2 and p‑STAT3 were downregulated by baricitinib in a dose‑dependent manner. Furthermore, addition of RO8191 restored the effect of baricitinib on the induction of oxidative stress, inflammation and osteogenic differentiation of PDLSCs exposed to LPS. Collectively, these findings suggested that baricitinib alleviated oxidative stress and inflammation and promoted osteogenic differentiation of LPS‑induced PDLSCs by inhibiting JAK/STAT signaling.
View Figures
View References

Related Articles

Journal Cover

February-2023
Volume 25 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang P, Shi F and Zhang Y: Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling. Exp Ther Med 25: 74, 2023
APA
Yang, P., Shi, F., & Zhang, Y. (2023). Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling. Experimental and Therapeutic Medicine, 25, 74. https://doi.org/10.3892/etm.2022.11773
MLA
Yang, P., Shi, F., Zhang, Y."Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling". Experimental and Therapeutic Medicine 25.2 (2023): 74.
Chicago
Yang, P., Shi, F., Zhang, Y."Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling". Experimental and Therapeutic Medicine 25, no. 2 (2023): 74. https://doi.org/10.3892/etm.2022.11773